Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lisaftoclax + daunorubicin + cytarabine
- Development stage
- Unknown
- Lead developer
- Ascentage Pharma
- Modality
- Small Molecules
- Administration
- Oral, Intravenous, Subcutaneous
01
Overview
Lisaftoclax + daunorubicin + cytarabine (LDA) is an investigational combination therapy being studied for the treatment of newly diagnosed intermediate- and high-risk acute myeloid leukemia (AML) in young adults. The regimen combines lisaftoclax (APG-2575), a selective, orally administered small-molecule BCL-2 inhibitor, with the standard chemotherapy agents daunorubicin and cytarabine. Lisaftoclax works by blocking the anti-apoptotic BCL-2 protein, thereby sensitizing malignant cells to the cytotoxic effects of chemotherapy and promoting programmed cell death (apoptosis). This combination is designed to enhance the efficacy of the traditional '7+3' induction backbone in patients eligible for intensive chemotherapy.
- Other names
- LDA
02
Targets
DNA polymerase familyTOP2A (DNA topoisomerase II)DNABCL2L1 (B-cell lymphoma-extra large protein)
Beyond the preview
Go deeper on lisaftoclax + daunorubicin + cytarabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lisaftoclax + daunorubicin + cytarabine.